SCHEMBL412013

SCHEMBL412013

Brc1ccc2c(c1)c1ccccc1n2CC1CO1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.85
DHFR P00374 1/20 0.60
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
RAD52 P43351 1/20 0.49
TSPO P30536 2/20 0.48
LMNA P02545 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
TP53 P04637 2/20 0.44
KRAS P01116 2/20 0.44
ALDH1A1 P00352 3/20 0.42
HPGD P15428 2/20 0.42
DNM1 Q05193 2/20 0.41
SIGMAR1 Q99720 1/20 0.40
MAPK1 P28482 3/20 0.39
HTT P42858 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30694089 1.00 MAPT (0.85) MAPTDHFRMEN1KMT2ARAD52
SCHEMBL411024 0.92 MAPT (1.00) MAPTDHFRMEN1KMT2ARAD52
SCHEMBL409341 0.92 MAPT (1.00) MAPTDHFRMEN1KMT2ARAD52
SCHEMBL409340 0.92 MAPT (1.00) MAPTDHFRMEN1KMT2ARAD52
SCHEMBL31454826 0.92 MAPT (1.00) MAPTDHFRMEN1KMT2ARAD52
SCHEMBL15380522 0.85 DHFR (0.79) MAPTDHFRMEN1KMT2ALMNA
SCHEMBL409180 0.85 DHFR (0.79) MAPTDHFRMEN1KMT2ALMNA
SCHEMBL15380515 0.85 DHFR (0.79) MAPTDHFRMEN1KMT2ALMNA
SCHEMBL29558375 0.85 DHFR (0.79) MAPTDHFRMEN1KMT2ALMNA
SCHEMBL29558033 0.85 DHFR (0.79) MAPTDHFRMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117229196-A Salicylaldehyde carbazole compound and application thereof 贵州省茶叶研究所 2023-12-15 CN disclosed
US-10183011-B2 Anti-depression compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-01-22 US disclosed
US-10183011-B2 Anti-depression compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-01-22 US disclosed
US-20180318255-A1 Pro-Neurogenic Compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2018-11-08 US disclosed
US-20180127367-A1 Pro-Neurogenic Compounds NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2018-05-10 US disclosed
US-20180127367-A1 Pro-Neurogenic Compounds NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2018-05-10 US disclosed
US-20180127367-A1 Pro-Neurogenic Compounds NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2018-05-10 US disclosed
US-9962368-B2 Pro-neurogenic compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-05-08 US disclosed
US-9962368-B2 Pro-neurogenic compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-05-08 US disclosed
US-9962368-B2 Pro-neurogenic compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2018-05-08 US disclosed
US-8362277-B2 Pro-neurogenic compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-01-29 US disclosed
US-8362277-B2 Pro-neurogenic compounds BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2013-01-29 US disclosed
US-20120022096-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-01-26 US disclosed
US-20120022096-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-01-26 US disclosed
US-20120022096-A1 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-01-26 US disclosed
WO-2012006419-A2 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-01-12 WO disclosed
WO-2012006419-A2 PRO-NEUROGENIC COMPOUNDS BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-01-12 WO disclosed
US-20110003836-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-06 US disclosed
US-20110003836-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-06 US disclosed
US-20110003836-A1 Pro-Neurogenic Compounds BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2011-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022096-A1 PRO-NEUROGENIC COMPOUNDS BDNF, GAP43, DCX MAPT 136/4885DHFR 2444/4885MEN1 3423/4885
US-20180127367-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX MAPT 136/4885DHFR 2444/4885MEN1 3423/4885
US-20180318255-A1 Pro-Neurogenic Compounds BDNF, GAP43, DCX MAPT 136/4885DHFR 2444/4885MEN1 3423/4885
US-10183011-B2 Anti-depression compounds BDNF, DCX, GAP43 MAPT 142/4885DHFR 2190/4885MEN1 4295/4885
US-20110003836-A1 Pro-Neurogenic Compounds DCX, GAP43, BDNF MAPT 571/4885DHFR 2447/4885MEN1 3234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.